Clinical trial

Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

NCT04251182

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention 15mg T3D-959 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention 30 mg T3D-959 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention 45 mg T3D-959 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebos Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2021-03-01

PhasePHASE2

Conditions

Alzheimer Diseaseverified · MONDO: Alzheimer disease

Interventions

15mg T3D-959DRUG

30 mg T3D-959DRUG

45 mg T3D-959DRUG

PlacebosDRUG

Sponsors & collaborators

T3D Therapeutics, Inc.lead sponsor

National Institute on Aging (NIA)collaborator

Clinilabs, Inc.collaborator

Alzheimer's Associationcollaborator

Mapped research locations

DurhamNorth Carolina, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04251182 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.